• CHIR-99021 (CT99021): GSK-3 Stem Cell Guide

  2026-08-12

  CHIR-99021, also called CT99021, is a selective GSK-3α/β inhibitor used to modulate Wnt/β-catenin signaling in stem-cell and differentiation workflows. Its reported biochemical potency, solvent limitations, and pathway-dependent effects make assay design and exposure control essential.

• HBoV1 Replication, DNMT1, and NS1-Mediated RNA Control

  2026-08-11

  A 2024 PLOS Pathogens study shows that HBoV1 uses host DNA methylation and DNMT1 to support viral DNA synthesis while restraining RNA processing. Its key mechanistic insight is that NS1 promotes DNMT1 degradation through the ubiquitin–proteasome pathway, linking viral replication control with production of protein-encoding transcripts.

• Linezolid: Mechanism to Assay Strategy

  2026-08-11

  Linezolid is an oxazolidinone antimicrobial for rigorous studies of bacterial protein synthesis, MRSA, VRE, and bacterial pneumonia. This article connects its ribosomal mechanism with assay design and uses recent MmpL3 research to clarify how cross-domain evidence should—and should not—guide interpretation.

• Nipah Virus Polymerase Structure and Antiviral Design

  2026-08-10

  The reference study defines the architecture of the Nipah virus L-P polymerase complex using cryo-electron microscopy, X-ray crystallography, and integrative modelling. Its findings clarify how polymerase domains and the P-protein assemble, while identifying a metal-binding feature that may contribute to mRNA capping and future antiviral design.

• Cinoxacin: Mechanism, Spectrum, and UTI Evidence

  2026-08-09

  The reference study positioned Cinoxacin as a clinically useful quinolone antibiotic by integrating its bacterial DNA synthesis mechanism, activity against urinary gram-negative pathogens, pharmacokinetics, tolerability, and therapeutic evidence. Its main practical contribution was linking rapid urinary exposure and Enterobacteriaceae activity to treatment and prophylaxis strategies for bacterial urinary tract infections.

• Streptavidin – Cy5 for Reliable Cell Assays

  2026-08-08

  Learn how Streptavidin – Cy5 (SKU K1080) can strengthen biotin-based fluorescence workflows used alongside cell viability, proliferation, apoptosis, and cytotoxicity assays. This scenario-driven guide connects spectral selection, storage, controls, interpretation, and vendor evaluation to practical laboratory decisions.

• Propidium Iodide for Toxoplasma Cell Death Assays

  2026-08-07

  Learn how Propidium iodide turns membrane damage into a measurable endpoint for Toxoplasma gondii infection, GRA12 perturbation, viability testing, and cell-cycle profiling. The workflow combines practical PI staining with Annexin V, imaging, and genetic controls to distinguish parasite-associated host-cell injury from assay artifacts.

• Screening MMV Pandemic Box: New Leads Against MDR Pathogens

  2026-08-07

  This study systematically screened 247 compounds from the MMV Pandemic Response Box to identify agents effective against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and clinically relevant fungi. The findings highlight promising candidates for further development and inform future antimicrobial and biofilm inhibition research.

• TCF25 Controls Lysosomal Acidification in Glucose Starvation

  2026-08-06

  Ren et al. (2025) reveal TCF25 as a nutrient sensor that orchestrates metabolic adaptation and cell death during glucose deprivation by enhancing lysosomal acidification via V-ATPase. These findings clarify how cells shift from survival-promoting autophagy to lysosome-dependent cell death under metabolic stress, highlighting TCF25 as a potential therapeutic target for metabolic and ischemic diseases.

• HAUS1 as a Prognostic Biomarker and Immune Modulator in HCC

  2026-08-06

  The referenced study reveals that HAUS1 is highly expressed in hepatocellular carcinoma (HCC) and is linked to poor prognosis, tumor progression, and immune microenvironment alterations. These findings highlight HAUS1's potential as a diagnostic, prognostic, and therapeutic target, underscoring new avenues for biomarker-driven cancer research and therapy.

• Birinapant (TL32711): Advancing Apoptosis Induction in Cance

  2026-08-05

  Birinapant (TL32711) delivers reproducible, high-sensitivity apoptosis induction by targeting IAPs, enabling advanced cancer cell modeling and translational workflows. Recent biomarker discoveries, notably around MDM1 and p53, further empower researchers to overcome therapy resistance using this potent SMAC mimetic from APExBIO.

• Cefodizime: Precision Use of a Third-Gen Cephalosporin in Re

  2026-08-05

  Explore Cefodizime’s molecular pharmacology, immunomodulatory effects, and best practices for precise assay design. This in-depth analysis delivers actionable insights for leveraging this third-generation cephalosporin antibiotic in advanced microbiology research.

• Azathramycin A: Macrolide Antibiotic Innovation in TB Models

  2026-08-04

  Azathramycin A streamlines tuberculosis research by combining potent ribosomal inhibition with workflow flexibility, enabling precise modeling of Mycobacterium tuberculosis infection and resistance mechanisms. This guide translates biophysical insights and real-world protocols into actionable steps for advanced antibiotic discovery.

• Heparin Sodium: Applied Protocols for Thrombosis and Coagula

  2026-08-04

  Heparin sodium from APExBIO empowers precise modeling of blood coagulation and thrombosis, offering high solubility and robust anti-factor Xa activity in both classic and next-generation delivery workflows. This guide translates the latest mechanistic insights and experimental innovations—like exosome-inspired nanoparticle strategies—into practical steps and troubleshooting for researchers.

• Practical Guidance for Cell Counting Kit-8 (CCK-8) Plus Assa

  2026-08-03

  Cell Counting Kit-8 (CCK-8) Plus enables sensitive, rapid assessment of cell viability and cytotoxicity, addressing common workflow bottlenecks in proliferation and drug screening experiments. It is suited for high-throughput and quantitative applications in diverse cell types, but is not designed for endpoint measurements in non-viable or metabolically inactive samples.

16428 records 1/1096 page Next 12345 下5页 Last page